OncoMatch/Clinical Trials/NCT05761366

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Is NCT05761366 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Al18F-PSMA-BCH PET/CT for malignancy.

Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05761366Data as of Jun 2026Location: China

Treatment: Al18F-PSMA-BCH PET/CT — In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Al18F-PSMA-BCH PET/CT

Biomarker criteria

Required: FOLH1 positive-expressing

PSMA positive-expressing tumors

Prior therapy

Cannot have received: experimental drug or device

Received experimental drug or device within 1 month

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05761366 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior experimental drug or device disqualifies patients from enrollment.

Does this trial require FOLH1?

Yes, FOLH1 positive-expressing is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify